简介：AbstractLike antibody evaluation, using an effective antigen-specific T-cell immunity assessment method in coronavirus disease 2019 (COVID-19) patients, survivors and vaccinees is crucial for understanding the immune persistence, prognosis assessment, and vaccine development for COVID-19. This study evaluated an empirically adjusted enzyme-linked immunospot assay for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell immunity in 175 peripheral blood samples from COVID-19 convalescents and healthy individuals. Results of viral nucleic acid were used as the gold standard of infection confirmation. The SARS-CoV-2M peptide pool had higher sensitivity of 85% and specificity of 71% for the single peptide pool. For combined peptide pools, the parallel evaluation (at least one of the peptide pools is positive) of total peptide pools (S1&S2&M&N) had higher sensitivity (up to 93%), and the serial evaluation (all peptide pools are positive) of total peptide pools had higher specificity (up to 100%). The result of the serial evaluation was better than that of the parallel evaluation as a whole. The detection efficiency of M and N peptide pool serial evaluation appeared the highest, with a sensitivity of 80% and specificity of 93%. This T-cell immunity detection assay introduced in this report can achieve high operability and applicability. Therefore, it can be an effective SARS-CoV-2-specific cellular immune function evaluation method.

简介：AbstractRecently, death from herpes B virus (Cercopithecine Herpesvirus 1) infection was reported in China, reminding us to be alert to the risk of transmission and infection with herpes B virus. Herpes B virus is a zoonotic pathogen that can cause fatal encephalomyelitis in humans. The virus naturally infects rhesus monkeys, causing diseases like human herpes simplex virus (HSV) infection, which are often asymptomatic or mild in the rhesus macaque. However, herpes B virus infection can be fatal to humans. Without timely treatment, the mortality rate of herpes B virus infection is as high as 70%-80%. To date, approximately 50 cases of human herpes B virus (HBV) infection have been reported worldwide. Most cases are related to direct contact with macaques, such as scratching, biting, or mucosal contact with monkey body fluids or secretions. Although the risk of human-to-human transmission is low, the widespread prevalence of the virus among monkeys, the high mortality of infected persons, and the severe neurological sequelae of survivors render this virus an important zoonotic pathogen that threatens human beings. Biorisk-related training programs for at risk personnel and timely treatment after exposure to the B virus can reduce infection rate and mortality. The early initiation of antiviral therapy prevents severe disease or death after the rapid diagnosis of human B virus disease. Identification of risk factors is essential in controlling the spread of the herpes B virus in the population at risk.